Vista Pharmaceuticals Ltd
BSE:524711
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vista Pharmaceuticals Ltd
Income from Continuing Operations
Vista Pharmaceuticals Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vista Pharmaceuticals Ltd
BSE:524711
|
Income from Continuing Operations
-₹76.9m
|
CAGR 3-Years
-80%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-12%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Income from Continuing Operations
₹55.2B
|
CAGR 3-Years
15%
|
CAGR 5-Years
16%
|
CAGR 10-Years
11%
|
|
|
Cipla Ltd
NSE:CIPLA
|
Income from Continuing Operations
₹45.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
15%
|
CAGR 10-Years
10%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Income from Continuing Operations
₹105.8B
|
CAGR 3-Years
35%
|
CAGR 5-Years
41%
|
CAGR 10-Years
7%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Income from Continuing Operations
₹46.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
32%
|
CAGR 10-Years
8%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Income from Continuing Operations
₹22.7B
|
CAGR 3-Years
40%
|
CAGR 5-Years
14%
|
CAGR 10-Years
4%
|
|
Vista Pharmaceuticals Ltd
Glance View
Vista Pharmaceuticals Ltd. engages in the manufacture and market of pharmaceutical products. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2003-07-21. The firm also sells the products to its related companies, which are engaged in the manufacture of formulations. The company offers over-the-counter and prescription generic drug products, consisting of tablets, capsules and liquids covering various therapeutic categories. Its products include tablet dosage forms in the United States market, such as Sulfamethoxazole & Trimethoprim, Acetaminophen, Bismuth Subsalicylate, Bismuth Subgallate, Ferrous Gluconate, Ferrous Sulfate, Pyrantel Pamoate and Isoxsuprine HCl and tablet dosage forms in the non-United States market, such as Aspirin, Atenolol, Mebendazole, Nefidipine, Quinine Sulfate, Ranitidine HCl, Magnesium Trisilicate Compound, Aluminium Hydroxide, Folic Acid and Captopril. Its capsule dosage forms in the non-United States market include Indomethacin, Piroxicam and Nefidipine.
See Also
What is Vista Pharmaceuticals Ltd's Income from Continuing Operations?
Income from Continuing Operations
-76.9m
INR
Based on the financial report for Dec 31, 2025, Vista Pharmaceuticals Ltd's Income from Continuing Operations amounts to -76.9m INR.
What is Vista Pharmaceuticals Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-12%
Over the last year, the Income from Continuing Operations growth was -151%. The average annual Income from Continuing Operations growth rates for Vista Pharmaceuticals Ltd have been -80% over the past three years , -8% over the past five years , and -12% over the past ten years .
